Scholarlink

<p><i>Acteoside</i>, a phenylethanol glycoside, possesses various pharmacological properties. The aim of this study was to investigate the mechanism of its anti-obesity effects on high-fat diet (HFD)-induced obese mice, as well as to evaluate the anti-obesity effects of its two active metabolites, <i>caffeic acid</i> and <i>hydroxytyrosol</i>. Mice were randomly divided into six groups in the first part experiment and five groups in the second part experiment as follows: control diet group; control diet + <i>acteoside</i> at 150&#xa0;mg/kg/day group; HFD group; HFD + orlistat at 20&#xa0;mg/kg/day group; HFD + caffeic acid at 45&#xa0;mg/kg/day group; HFD + hydroxytyrosol at 40&#xa0;mg/kg/day group; HFD + <i>acteoside</i> at 75&#xa0;mg/kg/day group; and HFD + <i>acteoside</i> at 150&#xa0;mg/kg/day group. The results showed that <i>acteoside</i> exhibited more pronounced anti-obesity effects compared with its two active metabolites. <i>Acteoside</i> supplementation reduced body weight and white adipose tissue (WAT) weight and improved glucose tolerance and insulin sensitivity in obese mice, as well as partially reverse hepatic damage and fat accumulation. In addition, <i>acteoside</i> induced the production of brown adipose tissue (BAT) when compared with <i>caffeic acid</i> and <i>hydroxytyrosol</i>, as well as promote a thermogenesis program in BAT and activate AMPK and HSL signaling in both WAT and BAT. Furthermore, high-dose <i>acteoside</i> supplementation altered the gut microbiota by increasing the abundance of <i>Akkermansia muciniphila</i> in obese mice. In summary, our results indicate that long-term <i>acteoside</i> supplementation may partially reverse obesity by stimulating adipose thermogenesis, modulating lipid metabolism, and altering the gut microbiota.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acteoside prevents high-fat diet-induced obesity by regulating brown adipose tissue production, lipid metabolism, and the gut microbiota

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月23日

查看全文
  • Wenyu Ma,
  • Chengyan Wang,
  • Xiangfeng Jiang,
  • Yueting Zeng,
  • Yiying Liao,
  • Bo Yi,
  • Shixiu Feng

摘要

Acteoside, a phenylethanol glycoside, possesses various pharmacological properties. The aim of this study was to investigate the mechanism of its anti-obesity effects on high-fat diet (HFD)-induced obese mice, as well as to evaluate the anti-obesity effects of its two active metabolites, caffeic acid and hydroxytyrosol. Mice were randomly divided into six groups in the first part experiment and five groups in the second part experiment as follows: control diet group; control diet + acteoside at 150 mg/kg/day group; HFD group; HFD + orlistat at 20 mg/kg/day group; HFD + caffeic acid at 45 mg/kg/day group; HFD + hydroxytyrosol at 40 mg/kg/day group; HFD + acteoside at 75 mg/kg/day group; and HFD + acteoside at 150 mg/kg/day group. The results showed that acteoside exhibited more pronounced anti-obesity effects compared with its two active metabolites. Acteoside supplementation reduced body weight and white adipose tissue (WAT) weight and improved glucose tolerance and insulin sensitivity in obese mice, as well as partially reverse hepatic damage and fat accumulation. In addition, acteoside induced the production of brown adipose tissue (BAT) when compared with caffeic acid and hydroxytyrosol, as well as promote a thermogenesis program in BAT and activate AMPK and HSL signaling in both WAT and BAT. Furthermore, high-dose acteoside supplementation altered the gut microbiota by increasing the abundance of Akkermansia muciniphila in obese mice. In summary, our results indicate that long-term acteoside supplementation may partially reverse obesity by stimulating adipose thermogenesis, modulating lipid metabolism, and altering the gut microbiota.

Graphical abstract